Concepedia

Intratumoral immunocytokine treatment results in enhanced antitumor effects

Erik E. Johnson, Hillary D. Lum, Alexander L. Rakhmilevich, Brian E. Schmidt, Meghan Jo'An Furlong, Ilia N. Buhtoiarov, Jacquelyn A. Hank, Andrew Raubitschek, David Colcher, Ralph A. Reisfeld,

Cancer Immunology Immunotherapy · 2008 · 52 citations · 37 references

DOIFull text

Open access

Concepts

References

37

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.

N K Cheung, Hillard M. Lazarus, Floro Miraldi et al. · Journal of Clinical Oncology · 1987 · 415 citations

, , +15

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.

James J. Mulé, Jin‐Hao Yang, R L Afreniere et al. · The Journal of Immunology · 1987 · 212 citations

, , +13

IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2

Connie Jackaman, Christine Bundell, Beverley F. Kinnear et al. · The Journal of Immunology · 2003 · 202 citations · Full text

, , +17

A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group

Kaci L. Osenga, Jacquelyn A. Hank, Mark R. Albertini et al. · Clinical Cancer Research · 2006 · 180 citations · Full text

, , +17

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.

Stephen D. Gillies, Edward B. Reilly, Kin-Ming Lo et al. · Proceedings of the National Academy of Sciences · 1992 · 179 citations

, , +17